INTRODUCTION
Prostate cancer (PCa) is the most common visceral cancer in Western countries and the second most lethal malignancy amongst men in the USA [1] . In 2010, an estimated 217 730 American men were newly diagnosed with prostate cancer, and 32 050 died of the disease [2] . In Europe, PCa has an incidence of 214 cases per 100 000 men, outnumbering lung and colorectal cancers [3, 4] . To date, the estimated lifetime risk of PCa is 17%, which is likely to rise with the observed increase in life expectancy. However, not all men are destined to die of their cancer. PCa remains a heterogeneous disease with inconsistent natural history varying from indolent to highly aggressive. Many cases of PCa are considered subclinical, likely to pose little threat to longevity or quality of life. This is reflected in the high incidence of PCa detected at autopsies in undiagnosed men [5] , and the high prevalence of indolent disease with an exceedingly low risk of progression found at radical prostatectomy [6, 7] . On the contrary, the relative risk of PCa-related mortality in men with high-risk prostate cancer (HRPCa) is substantial despite optimal therapy, and has been estimated at 14.2% after radical prostatectomy and 14.3% after external beam radiation therapy (EBRT) [8] . Thus, a major challenge remains the identification of men with HRPCa who face the highest risk of treatment failure, disease progression, and cancer-related mortality [9] . Contemporary evidence indicates that HRPCa is diagnosed in 13-19% of PCa patients treated with radical prostatectomy or EBRT [10] [11] [12] [13] .
To date, there is no consensus on the optimal management of HRPCa. Available therapeutic options include monotherapy by radical prostatectomy, or combined modality approaches that include local treatment such as EBRT along with androgen deprivation therapy (ADT) or chemotherapy. HRPCa patients are at increased risk of locally advanced or micrometastatic disease [14] , and therefore it is reasonable to employ a more aggressive treatment plan targeting the local as well as systemic components of the disease.
The categorization of patients into accurate-risk groups is important to ensure appropriate local therapy and allow adequate enrollment in clinical trials. This review aims to discuss and elaborate on the contemporary definitions of HRPCa and their implications on diagnostic and therapeutic approaches.
DEFINING HIGH-RISK PROSTATE CANCER
In spite of the outstanding advances in the understanding of PCa pathogenesis and the exploration of novel biomarkers, the most currently acknowledged criteria used to risk-stratify PCa patients remain the clinical stage determined by a digital rectal examination, the biopsy Gleason score, and the pretreatment prostate-specific antigen (PSA) level. No single criterion -stage, grade, or pretreatment PSA -can adequately identify cancers with high propensity of progression after local therapy. Although various risk classification systems that incorporate these three factors have been developed, standardized criteria that define HRPCa are still lacking [15] . Reliance on simple risk-stratification schemes, that are readily available with a glance at a medical record, has often led patients and physicians to classify patients with localized and curable disease as high risk. This causes an unjustifiable preference of ADT, which offers no cure over local definitive therapy [16] . Table 1 summarizes the contemporary and most widely used definitions of HRPCa. In a landmark paper published in 1998, D'Amico et al. [17] established the most popular risk-stratification system for PCa based on clinical data obtained from 1872 patients who underwent radical prostatectomy or EBRT with curative intent. HRPCa was defined as having any of the following risk factors, predicting greater than 50% probability of cancer recurrence after local therapy: clinical stage T2c or higher, a pretreatment PSA greater than 20 ng/ml, or a biopsy Gleason score of at least 8. The American Urological Association and the UK National Institute for Health and Clinical Excellence have endorsed the D'Amico high-risk criteria [18, 19] , whereas the European Association of Urology and National Comprehensive Cancer Network (NCCN) guidelines have narrowed the risk group by restricting the clinical stage criterion to T3a and above rather than T2c [3, 20] . The Radiation Therapy Oncology Group (RTOG) uses a risk-stratification scheme which consists of PSA 20-100 ng/ml, biopsy Gleason score at least 7, and any clinical T stage; or PSA below 100 ng/ml, Gleason score at least 8, and clinical
KEY POINTS
High-risk prostate cancer is a lethal disease accounting for an estimated 15% of prostate cancer cases.
Various contemporary high-risk disease definitions are available which differ considerably and harbor significant therapeutic ramifications.
The D'Amico risk classification is the most widely used but lacks specificity and includes a very heterogeneous group of patients.
Incorporating several known risk factors together, adding endorectal MRI findings, pretreatment PSA velocity, and additional data from prostate biopsies may produce a more precise high-risk disease definition. The Cancer of the Prostate Risk Assessment score [22] GS, Gleason score; PSA, prostate-specific antigen.
stage T2c [21] . 
THE HETEROGENEITY OF THE HIGH-RISK CRITERIA
The numerous definitions of HRPCa and lack of consensus on a single precise definition represent a major barrier for patient counseling, comparative assessment of treatment outcomes, and the design of randomized trials [28] . The considerable heterogeneity in outcomes of patients with HRPCa after radical prostatectomy depending on the definition used has been highlighted in several studies [26, 29] . In general, currently used clinical criteria to identify HRPCa encompass a heterogeneous group of patients, some of whom can be cured by local therapy alone and others in whom local therapy may not suffice and additional systemic therapy is required. Several examples are outlined below.
THE PROSTATE-SPECIFIC ANTIGEN LEVEL
A PSA cut-off of 20 ng/ml has been used by several investigators to classify tumors as belonging to the high-risk category. Yossepowitch et al. [30] demonstrated that the 10-year prostate cancer-specific mortality (PCSM) was 9% in patients with a PSA greater than 20 ng/ml, compared with 3% in those with PSA 20 ng/ml or less [hazard ratio 3.4; 95% confidence interval (CI) 2.3-5.4]. Similarly, Stephenson et al. [31] found the estimated 15-year PCSM to be 22% in patients with PSA of 20.1-50 ng/ml and 4-11% in those with PSA less than 20 ng/ml. Whereas these data suggest that a PSA greater than 20 ng/ml can be considered as a reliable determinant of treatment failure, classifying patients into the high-risk category solely based on their PSA (as defined by the D'Amico criteria) is problematic. This is because PSA reflects not only the burden of cancer, but also the volume of benign prostatic hyperplasia and inflammation [32] . Spahn et al. [33] , for example, found substantial heterogeneity in outcomes among patients with PSA greater than 20 ng/ml. In their study, a fifth of the patients with high PSA (>20) had organ-confined disease (OCD), 75% had negative lymph nodes, and their 10-year cancer-specific survival (CSS) was 89%, consistent with previous studies [15, 34] . Thus, using the absolute pretreatment PSA level as a single criterion for high-risk disease may overestimate the risk of relapse and expose many patients to unwarranted aggressive multimodal therapy. Another application of the PSA level as a solitary parameter to define HRPCa is the pretreatment PSA velocity [35] . D'Amico's group reported that a PSA velocity of above 2.0 ng/ml/year, computed with the PSAs obtained within 18 months prior to diagnosis, was associated with a seven-fold increased risk of mortality following radical prostatectomy [35] . This high-risk criterion, however, could not be validated in other independent cohorts [15, 30, 36] , questioning its general applicability to the overall population of PCa patients.
INCORPORATING SEVERAL RISK FACTORS
Incorporating several high-risk factors may allow us to better distinguish distinct risk groups and identify true high-risk patients. Yet, risk grouping of patients with similar -albeit not identical -disease features may result in heterogeneity within a risk group and reduced predictive accuracy. D'Amico's venerable high-risk definition would place a person with nonpalpable (PSA 5.8), single core Gleason 8 tumor in the same risk group as another person with clinical T3 and multiple cores of Gleason 9 tumor. Some high-risk definitions may yield a substantial proportion of 'high-risk' patients who have OCD and no evidence of recurrence at 10 years [15] . In a cancer of the prostate strategic urologic research endeavor (CaPSURE) study comprising 1701 men, Mitchell et al. [37] showed that men with intermediate and high-risk disease according to D'Amico had, in fact, similar rates of relapse (26 and 31% at 5 years, respectively), emphasizing the limited discriminating ability of this high-risk definition.
To overcome this shortcoming, several authors have suggested to define high risk by adding several risk factors, thus restricting the definition to patients with the greatest probability of treatment failure. Briganti et al. [38 OCD after radical prostatectomy. Patients with 1, 2, and 3 NCCN risk factors harbored OCD in 45, 23, and 9% of cases, respectively (P < 0.001) [38 & ]. Nguyen et al. [39] showed that the number of assigned risk factors was associated not only with adverse pathological features but also with the risk of cancer-related mortality after surgery. Specifically, compared to patients with only one risk factor, the adjusted PCSM hazard ratio was 2.3 (95% CI 1.1-4.8; P ¼ 0.03) for those with two risk factors, 5.4 (95% CI 2.7-10.7; P < 0.0001) for those with three risk factors, and 13.6 (95% CI 6.3-29.2; P < 0.0001) for those with three risk factors and pretreatment PSA velocity above 2.0 ng/ml/year [39] . Spahn et al. [33] showed that combining PSA greater than 20 ng/ml and clinical stage above cT2c or PSA greater than 20 ng/ml and biopsy Gleason score above 7 was associated with adverse pathology and inferior survival compared to PSA above 20 alone. Similar findings were also documented after radiation therapy for PCa. Zelefsky et al. [40] had noted that incorporating a number of risk factors together (>cT2, pretreatment PSA 10.0 ng/ml, and Gleason score 7) was associated with higher biochemical relapse rates after three-dimensional conformal radiation therapy compared to each factor alone.
INTEGRATING ENDORECTAL MRI IN DEFINING HIGH-RISK TUMORS
Whereas clinical stage, pretreatment PSA, and biopsy Gleason score continue to serve as the primary determinants of the risk of treatment failure, endorectal MRI has recently emerged as an adjunct powerful tool to evaluate the local extent of the tumor. Several studies suggested that local staging with MRI in men with seemingly high-risk disease may be of incremental prognostic value [41, 42] . Muglia et al. [43 & ] reported that almost 4% of patients with PCa have gross locally advanced disease at endorectal MRI, defined as unequivocal extracapsular extension or seminal vesicle invasion. These patients had significantly worse prognosis compared to matched controls at identical risk according to D'Amico's criteria but without the same ominous features on MRI [43 & ]. Similarly, D'Amico et al. [44] demonstrated that in 1025 patients undergoing radical prostatectomy for PCa, T3 disease detected at preoperative endorectal MRI was associated with worse prognosis in patients with intermediate and high-risk disease but not in those with low-risk disease. In another study examining the role of preoperative endorectal MRI in deciding whether to resect or preserve the neurovascular bundle, MRI was found most useful in high-risk patients, changing the surgical plan for 28/72 neurovascular bundles in the high-risk subset [45] . According to the pathologic findings, the change was appropriate in 26/28 cases (93%). These studies suggest that endorectal MRI to evaluate the local extent of disease may prove particularly useful in high-risk cancers, and could potentially be integrated into available high-risk definitions.
THE OPTIMAL HIGH-RISK PROSTATE CANCER DEFINITION
To be clinically useful, criteria defining HRPCa should reliably distinguish patients whose cancer is amenable to cure with local therapy alone from those who may require additional systemic therapy [30] . An optimal high-risk definition should comprise and balance between a high level of sensitivity, whereby all patients with locally advanced or occult metastatic disease are included, and with an acceptable level of specificity, whereby patients with otherwise OCD are excluded. If high risk is determined by lenient criteria, increased sensitivity will be achieved at the expense of decreased specificity, thus including patients with OCD and subjecting them to unnecessary multimodal therapy with its attendant morbidity. On the contrary, if high-risk disease is defined by stringent criteria (e.g. incorporating several risk factors together), the improved specificity may be achieved at the expense of decreased sensitivity. The latter would result in precluding patients with locally advanced disease or occult metastases from receiving the necessary additional local and systemic therapy. Until novel biomarkers that predict more accurately the likelihood of spread beyond the prostate are available in routine clinical use, the optimal definition of HRPCa would likely be achieved with continuous multivariable models such as nomograms that provide a more accurate method of risk stratification and reliably predict the probability of failure in the individual patient [15] .
CONCLUSION
To date, there is no consensus on a single precise definition of HRPCa. Several high-risk definitions are available, none of which is able to accurately discriminate between patients amenable to cure with local therapy alone from those who require multimodal systemic therapy. Novel molecular markers which can significantly enhance the prediction of relapse following therapy and identify locally advanced and occult metastatic disease are needed. Until such markers are discovered, additional information derived from prostate biopsy, pretreatment PSA velocity, endorectal MRI findings, and incorporation of several known highrisk criteria may be used to yield a better prediction tool and enable more accurate discrimination between the different risk groups. Using contemporary definitions to categorize tumors as high risk should not disqualify patients from receiving local definitive therapy with curative intent.
